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Abstract 
BACKGROUND: Preclinical studies have demonstrated that renin-angiotensin system (RAS) signalling has 
strong tumour-promoting effects and RAS inhibition was associated with improvement in the overall survival in 
some cancer types including hepatocellular carcinoma (HCC). 
OBJECTIVE: We aimed to investigate the effect of angiotensin-converting enzyme inhibitors (ACEIs) or 
angiotensin-II-receptor blockers (ARBs) on the survival of mice with diethylnitrosamine (DEN) induced HCC. 
METHODS: HCC was induced by weekly i.p. administration of DEN. Mice were treated with sorafenib (SO) (30 
mg/kg), perindopril (PE) (1 mg/kg), fosinopril (FO) (2 mg/kg), losartan (LO) (10 mg/kg), PE (1 mg/kg) + SO (30 
mg/kg), FO (2 mg/kg) + SO (30 mg/kg), or LO (10 mg/kg) + SO (30 mg/kg). Survival analysis was done using the 
Kaplan-Meier method, and the log-rank test was used for assessing the significance of difference between 
groups. 
RESULTS: The administration of PE, FO and LO as monotherapy or as combined with SO resulted in marked 
improvement in the liver histologic picture with no impact on overall survival of mice. 
CONCLUSION: Interfering the RAS either through the inhibition of ACE or the blockade of angiotensin II type 1 
(AT1) receptors has similar effects on the liver of DEN-induced HCC mice and is not associated with longer 
survival due to detrimental effects of DEN on other organs. Hence, repetitive administration of DEN in such 
models of HCC is not suitable for mortality assessment studies. 
 
 
 
Introduction 
 
Hepatocellular carcinoma (HCC), a major 
health problem is representing about 75% of primary 
liver cancers [1] [2], is considered the second most 
common cause of cancer-related mortality worldwide 
[3] and is characterised by poor prognosis. Risk 
factors for HCC have been described including 
infections with chronic viral hepatitis, non-alcoholic 
steatohepatitis (NASH) and alcohol consumption [4]  
[5] [6].  
Treatment options of HCC are still limited and 
depend on liver function and patient condition [7]. 
Patients are usually diagnosed at advanced tumour 
stages as HCC patients are frequently asymptomatic. 
The oral multikinase inhibitor sorafenib, remains the 
only efficacious treatment, currently showing a certain 
degree of benefit [8] [9] and provides a modest 
prolongation of the median overall survival (OS) (2.8 
months) [10]. Regorafenib, a closely related tyrosine 
kinase inhibitor demonstrated an increase in OS as a 
second-line (next to failure of sorafenib) [11]. None of 
the other agents tested showed a survival benefit 
versus sorafenib or placebo [12]. Therefore, a critical 
need exists to evaluate possible alternative strategies 
for the effective improvement in the survival of HCC 
patients. 
There is emerging evidence that Angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) have beneficial effects in 
patients with HCC [13]. De Paepe, Verstraeten [14] 
reported that angiotensin II (Ang II) type 1 (AT1) 
receptor may be an essential step in the development 
of breast cancer, also it was reported that RAS 
inhibition was associated with reduced risk of breast 
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cancer recurrence [15]. Furthermore, other studies 
revealed that ACEIs or ARBs might decrease the risk 
of esophageal [16] and keratinocyte [17] carcinoma. 
Their use was also associated with increased 
response in rectal cancer [18] and longer OS in 
patients with renal cell, pancreatic, brain, and lung 
cancer [19] [20]. However, little is known about the 
impact of RAS inhibition on the OS of HCC on the 
experimental and clinical sides. 
Therefore, the present study was conducted 
to examine beneficial effects of RAS inhibition on liver 
histology and to assess the association between RAS 
inhibition and survival using the ACEIs, perindopril 
(PE) and fosinopril (FO) and the ARB, losartan (LO) 
by comparing their effects to sorafenib (SO) using a 
model of diethylnitrosamine (DEN)-induced HCC in 
mice. 
 
 
Material and Methods 
 
A total of 270 male CD-1 mice weighing 12 g 
were used in the current study. They were purchased 
from Schistosome Biological Supply Program at 
Theodor Bilharz Research Institute (SBSP-TBRI), 
Egypt and housed in polycarbonate cages in an 
animal facility certified by the association for 
assessment and accreditation of laboratory animal 
care and maintained in accordance with the National 
Institute of Health guide for the care and use of 
laboratory animals, Egypt. All experimental 
procedures were approved by local authorities at the 
SBSP-TBRI and by the Ethical Committee for Animal 
Handling at Zagazig University (ECAHZU), Egypt. All 
of the mice were fed rodent chow (23% protein and 
4% fat) and received water ad libitum. They were kept 
under standard laboratory conditions of (21 Co, 45-
55% humidity) and exposed to a 12/12 light-dark 
cycle. The animals were allowed to acclimate for 1 
week before the experiments. 
Diethylnitrosamine (DEN) was diluted (1:100 
v/v) in saline. Perindopril, fosinopril and losartan were 
freshly prepared immediately before use by 
suspending in distilled water.  
Mice were divided into groups as follows: 
Group 1: normal mice received i.p. injections of 
normal saline once a week (n = 6). Group 2: DEN 
induced HCC mice (DIHCC) received i.p. injections of 
DEN (Sigma-Aldrich CAS: 55-18-5, St. Louis, MO, 
USA) (n = 60) once a week according to the following 
schedule (week1 (30 mg/kg), w2 (50 mg/kg), w3 (50 
mg/kg), w4 (70 mg/kg), w5 (100 mg/kg), w6→w16 (50 
mg/kg)). Group 3: DIHCC mice received 30 mg/kg 
sorafenib (Bayer Pharmaceuticals, AG, Berlin, 
Germany) (n = 30). Group 4: DIHCC mice received 1 
mg/kg perindopril (Servier Pharmaceutical Company, 
Suresnes, France) (n = 30). Group 5: DIHCC mice 
received 2mg/kg fosinopril (Bristol-Myers Squibb 
Pharmaceutical Company, New York, NY, USA) (n = 
30). Group 6: DIHCC mice received 10mg/kg losartan 
(Merck Pharmaceutical Company, Kenilworth, NJ, 
USA) (n = 30). Group 7: DIHCC mice received 
(1mg/kg perindopril + 30 mg/kg sorafenib) (n = 30). 
Group 8: DIHCC mice received (2 mg/kg fosinopril + 
30 mg/kg sorafenib) (n = 30). Group 9: DIHCC mice 
received (10 mg/kg losartan + 30 mg/kg sorafenib) (n 
= 30). Mice were administered suspension of drugs in 
distilled water by oral gavage daily starting from day 
45 of experiment and sacrificed by decapitation 16 
weeks post induction. 
The dose of sorafenib was selected based on 
previous studies [21] [22] [23]. On the other hand, the 
equivalent mouse doses of perindopril, fosinopril, and 
losartan were calculated by interpolating from the 
corresponding lowest effective human dose using 
approximate dose conversion factors described by 
Freireich et al., [24].  
Liver tissues were fixed in 10% neutral 
buffered formalin (pH 7.0) and embedded in paraffin. 
Sections (5 µm thick) from the paraffin blocks were 
stained with hematoxylin and eosin (H&E) for 
histopathological examination. HCC was graded as 
described by Theise, Curado [25]. 
Statistical analysis was performed using 
GraphPad Prism software version 6 (GraphPad 
Software Inc., La Jolla, CA, USA). For overall survival, 
the log-rank (Mantel-cox) test was used for assessing 
the significance of the difference between groups in 
the Kaplan-Meier analysis. P values ˂ 0.05 were 
considered significant.  
 
 
Results 
 
The representative histological appearance of 
liver specimens from untreated normal control mice 
showed hepatic lobules with intact lobular 
architecture. Liver cells are arranged in cords of one 
to two cell-thick, radiating from a central vein towards 
the lobular periphery with blood sinusoids in-between. 
Hepatocytes are polyhedral with abundant granular 
eosinophilic cytoplasm and one spherical nucleus with 
dispersed chromatin. Portal tracts are of normal shape 
and thickness. 
Sections of Liver from the DEN-treated mice 
showed loss of hepatic lobular architecture and 
enlarged hepatocytes with marked nuclear atypia, 
nuclear hyperchromasia, pleomorphism, increased 
nucleocytoplasmic ratio and appearance of tumour 
giant cells. Also, different sections showed HCC 
(grade 3) characterised by malignant hepatocytes 
surrounded by fibrotic stroma that were infiltrated by 
mononuclear inflammatory cells. 
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Figure 1: Representative light micrographs from: (a) normal control 
showing normal liver histology with radial arrangement of 
hepatocyte rays around central veins (arrows) that are separated by 
sinusoids; (b) DEN-treated mice showing HCC of grade (3) with 
disturbed architecture and loss of lobular pattern, hepatocellular 
atypia, pleomorphism, intralobular inflammatory infiltrate 
(arrowheads), malignant hepatocytes with moderate to marked 
nuclear anaplasia (arrows). Moreover, intralobular inflammatory 
infiltrates, fibrous tissue deposition (arrowheads) and congested 
blood vessels are evident. Micrographs from mice treated with 
sorafenib, (c), perindopril (d), fosinopril (e), losartan (f), perindopril 
plus sorafenib (g), fosinopril plus sorafenib (h), and losartan plus 
sorafenib (i) showing regression of malignant changes with almost 
restoration of lobular architecture and lowering of the grade of HCC 
to grade 1 (H&E x100) 
  
The representative histological appearance of 
liver tissue specimens from DIHCC mice treated with 
Sorafenib showed regression of malignant changes 
and lowering of the grade of HCC to grade 1 with 
almost restoration of lobular architecture 
 
Figure 2: Kaplan-Meier survival curves of (a) DEN vs normal 
control; (b) perindopril vs sorafenib; (c) fosinopril vs sorafenib; (d) 
losartan vs sorafenib. Statistical analysis was performed using log-
rank test (Mantel-  x      d).   v    s ˂0.05 w       sid   d 
significant 
 
The administration of perindopril, fosinopril, or 
losartan either as monotherapy or combined with 
sorafenib improved the histological picture of liver 
showing moderate regression of malignant and 
inflammatory changes with lowering of the grade of 
HCC to grade 1 (Figure 1). 
 
Figure 3: Kaplan-Meier survival curves of (a) (perindopril+sorafenib) 
vs sorafenib; (b) (fosinopril+sorafenib) vs sorafenib; (c) 
(losartan+sorafenib) vs sorafenib. Statistical analysis was 
performed using log-rank test (Mantel-  x      d).   v    s ˂0.05 
were considered significant 
 
Kaplan-Meier survival curves are represented 
in Figure 2, 3 and 4. Normal mice had no mortality at 
the end of the experimental period (Figure 2a). On the 
other hand, DEN-treated mice had a higher mortality 
rate with a median survival time of 86 days (95% CI of 
ratio: 0.02 to 0.16) vs normal control (Figure 2a). The 
administration of sorafenib (Figure 2, 3 and 4), 
perindopril (Fig. 2b), fosinopril (Figure 2c), or losartan 
(Figure 2d) resulted in slight increases in the median 
survival time as follows: 96 days (95% CI of ratio: 0.29 
to 1.4), 113 days (95% CI of ratio: 0.29 to 1.4), 100 
days (95% CI of ratio: 0.41 to 1.5), and 106 days 
(95% CI of ratio: 0.35 to 1.46), respectively.  
 
Figure 4: Kaplan-Meier survival curves of (a) monotherapy; (b) 
combination drug therapy; (c) monotherapy and combination 
therapy in DEN-treated mice. Statistical analysis was performed 
using log-rank test (Mantel-  x      d).   v    s ˂0.05 w    
considered significant 
 
Moreover, the administration of (perindopril + 
sorafenib, Figure 3a), (fosinopril + sorafenib, Figure 
3b), or (losartan + sorafenib, Figure 3c) resulted in 
slight increases in the median survival time as follows: 
114 days (95% CI of ratio: 0.3 to 1.38), 100 days 
(95% CI of ratio: 0.41 to 1.51) and 106 days (95% CI 
of ratio: 0.34 to 1.46). However, log-rank analysis for 
comparison of survival times revealed no significant 
differences in the lifespan of mice treated with the 
used drugs either as monotherapy (Figure 4a and 4c) 
or as adjunctive to sorafenib (Figure 4b and 4c) 
compared with DEN-treated mice. 
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Discussion  
 
The discovery of new agents or repurposing 
current medications is vital to improving the survival 
and prognosis of HCC patients. RAS inhibition is an 
interesting prospective target for the chemoprevention 
of HCC. Therefore, we aimed to determine whether 
RAS inhibitors improve the overall survival of HCC in 
mice making a direct comparison for their effects with 
sorafenib which is the only efficacious drug that was 
found to prolong survival only for (2.8 months) [10] in 
HCC patients. 
It is well documented that RAS plays an 
important role in promoting tumour growth [26] [27]. 
The use of ACEIs or ARBs has been found to inhibit 
different types of cancer including lung, breast, 
pancreatic, ovarian, prostatic, brain, colon, and liver 
cancer [28]. Furthermore, our lab demonstrated that 
the use of the ACEIs, perindopril and fosinopril and 
the ARB, losartan was found to decrease alpha-
fetoprotein significantly and affect regression of 
malignant changes with improvement in liver histology 
in HCC mice through multifaceted mechanisms 
including the inhibition of angiogenesis, profibrotic 
mediators and inflammatory pathways (unpublished 
data) 
Also, in the current study, combination 
therapy was evaluated to examine the potential 
augmenting effects of such safe agents when co-
administered with sorafenib experimentally. Notably, a 
similar combination was recently evaluated clinically in 
which authors stated that patients treated with 
sorafenib plus RAS inhibition had a better median 
overall survival (19.5 mo) compared to those treated 
with either sorafenib (10.9 mo) or RAS inhibition (9.7 
mo) alone (p = 0.043) [29]. Another observational 
study found that the use of ARBs during erlotinib 
treatment may prolong OS of patients with metastatic 
non-small cell lung cancer (NSCLC) [30].  
The selection of perindopril (a high tissue 
affinity ACEI) and fosinopril (a low tissue affinity ACEI) 
[31] [32] was planned to evaluate the concept of class 
effect or interchangeability regarding therapeutic and 
side effects of ACEIs [33] [34]. Moreover, we 
evaluated the effect of blocking RAS signalling 
through antagonising Ang II via blocking its AT1 
receptors using the ARB, losartan.  
HCC in DEN-treated mice was evident by the 
appearance of malignant enlarged hepatocytes upon 
histologic examination. The histologic picture of HCC 
in mice treated with DEN was improved after 
treatment with the selected ACEIs, perindopril and 
fosinopril and the ARB, losartan either as 
monotherapy or when combined with sorafenib. This 
was manifested as a regression of HCC from grade 
(3) to grade (1) indicating the inhibition of malignant 
transformation and lower tumour production rates. 
In the current study, DEN was used to induce 
HCC. Mice mainly develop liver tumours, but also 
gastrointestinal [35], skin, respiratory and 
haematopoietic tumours. The carcinogenic capacity of 
DEN is situated in its capability of alkylating DNA 
structures.  
The DEN-induced tumorigenesis is mediated 
through its metabolites formed through its 
bioactivation by cytochrome P450 (CYP) enzymes 
[36]. An ethyldiazonium ion is formed and causes 
DNA damage by reacting with DNA-bases 
(nucleophiles). DEN works in a dose-dependent 
manner [37] to induce HCC after a period of latency. 
Genetically, the DEN-model verifies to be a good 
representation of HCC connected with poor prognosis 
[38]. When adult mice are exposed to a short time 
weekly administration of DEN, it leads to a higher 
incidence of a tumour in a shorter time span. For 
example, administration of 35 mg⁄kg DEN to mice 
weekly leads to HCC after 20-35 weeks [39]. 
The lifespan of DEN-treated mice was 
significantly decreased compared with normal mice 
that showed no mortality. This is consistent with DEN-
induced systemic toxicity. The lifespan of mice did not 
significantly change by drug treatment compared with 
DEN-treated mice. The recent retrospective study 
published in 2017 by Pinter, Weinmann [29] 
demonstrated that the overall survival was increased 
in patients with HCC by the inhibition of RAS. The 
discrepancy between our results and the results of 
this study might be attributed to the repetitive 
administration of DEN that can have a detrimental 
impact on animals’ survival because DEN can affect 
the development of aggressive metastatic lesions in 
the lungs [40] [41]. Also, we noticed that some 
animals developed solid metastatic tumours 
distributed all over the body particularly in the thigh.  
The current study unveiled some interesting 
findings. First, the histologic picture of liver tissues 
was improved upon treatment with perindopril, 
fosinopril, or losartan as monotherapy or as adjunctive 
therapy to sorafenib and was comparable to each 
other and to that of sorafenib. These results 
demonstrate that the tissue affinity of the ACEI has no 
impact on its hepatoprotective effect in this model of 
HCC, and that is interfering the RAS either through 
the inhibition of ACE or the blockade of AT1 receptors 
has the same histologic benefit. However, perindopril 
seems more promising because perindopril-treated 
mice showed the highest survival either as 
monotherapy or when combined to sorafenib despite 
statistical insignificance. Hence, perindopril needs 
further evaluation with changing doses and therapy 
duration.  
Second, despite the promising effects of 
perindopril, fosinopril, or losartan for managing HCC 
as monotherapy, they failed to produce an additive 
pronounced improvement from the histopathological 
view when administered in combination with 
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sorafenib. Based on the current data, it is not 
imaginable to explain the lack of the additive effect of 
the drugs used and sorafenib. Therefore, a 
pharmacokinetic study is needed to examine whether 
inhibitory effects of sorafenib on phase I enzymatic 
reactions might affect the metabolic activation of the 
prodrugs, perindopril, fosinopril and losartan.  
Some studies described that sorafenib could 
induce mild liver dysfunction [42] [43] or severe 
hepatitis [44]. Metabolic dysfunction has been 
suggested as a mechanism for sorafenib-induced liver 
injury [45]. Consequently, another study is needed to 
examine the effect of RAS inhibitors on the sorafenib-
induced liver injury, suggesting augmentation of the 
deleterious effects of sorafenib on the liver tissue by 
concomitant administration of RAS inhibitors providing 
an alternative explanation for the lack of more 
improvement upon histological examination.  
 In conclusion, the present results provide a 
potential for the therapeutic benefits of ACEIs and 
ARBs in liver tissues suggesting the prospective use 
of ACEIs or ARBs in managing patients with HCC 
either alone or in combination with other interventions. 
Furthermore, a long-term repetitive administration of 
DEN is not suitable to study survival in experimental 
animals due to detrimental effects on other organs 
particularly respiratory and haematopoietic systems. 
Alternatively, single dose or short-term administration 
of DEN with a longer latency time is the most suitable 
model for performing survival analysis in rodents.  
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